Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
Eli Lilly & Co: Buy Rating Backed by Promising Orfoglipron Trials and Strong Pharmaceutical Pipeline
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Argus Research Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
Argus Research analyst Jasper Hellweg maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday. The company’s shares ...
BioSpace7h
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves on to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
DePauw7h
Fall 2024 Dean’s List recognizes exceptional academic achievements
DePauw University is pleased to announce the exceptional scholars who have attained Dean's List honors for the Fall 2024 term.
The New York Times11h
New York Times - Top Stories
House G.O.P. Floats Medicaid Cuts and More to Finance Trump’s Huge Agenda President Trump wants a massive tax cut and immigration crackdown bill. Republicans must decide what to cut to help pay ...